UBP316 is a potent and selective kainate receptor GluK1 (GluR5) antagonist (Kb = 1.4 nM); it effectively blocks ATPA (a GluK1-selective agonist)-induced field excitatory postsynaptic potentials (fEPSPs) and the inhibition of monosynaptically evoked GABAergic transmission.